10-Q: Utah Medical Products Reports Lower Sales and Earnings in Q3 2024, But Maintains Strong Financial Position

Utah Medical Products experienced a decrease in sales and earnings in the third quarter of 2024, primarily due to reduced OEM sales and Filshie Clip System sales, but maintained a strong balance sheet.

Summary

• Utah Medical Products (UTMD) reported a decrease in net sales for both the three and nine months ended September 30, 2024, compared to the same periods in 2023.
• Net sales for the third quarter of 2024 were $10.005 million, a 20% decrease from $12.505 million in the third quarter of 2023.
• For the nine months ended September 30, 2024, net sales were $31.745 million, a 16.2% decrease from $37.891 million in the same period of 2023.
• The decline in sales was primarily attributed to lower sales to a major OEM customer, PendoTECH, and decreased sales of the Filshie Clip System.
• Gross profit also decreased, with a 21.2% drop in the third quarter and an 18% drop for the nine-month period.
• Operating income decreased by 15.8% in the third quarter and 16.9% for the nine-month period.
• Net income decreased by 9.4% in the third quarter and 11.1% for the nine-month period.
• Earnings per diluted share (EPS) decreased by 5.2% in the third quarter and 8.7% for the nine-month period.
• Despite lower sales and earnings, UTMD's balance sheet remained strong with a higher current ratio and lower total liabilities.
• The company repurchased 196,592 shares for $13.259 million during the nine-month period and paid $3.222 million in dividends.
• Management expects a full-year 2024 revenue sales decline of 18% to 19% compared to 2023, with a similar decline in net income.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company maintains a strong financial position and is actively managing its capital, the significant decline in sales and earnings, along with ongoing litigation, creates a negative outlook. The company is also facing a difficult transition period.

Positives

• UTMD's balance sheet remains strong with a higher current ratio and lower total liabilities.
• The amortization of the CooperSurgical intangible asset ended in 2023, reducing operating expenses in 2024.
• The company has been actively repurchasing shares, which helps to support EPS.
• UTMD's management is focused on strategic initiatives to enhance future profitability.
• The company continues to generate positive cash flow from operations.
• The company has a strong desire and financial ability to repurchase shares at attractive prices.
• The company's working capital remains sufficient to meet normal operating needs.

Negatives

• Net sales decreased by 20% in Q3 2024 and 16.2% in 9M 2024 compared to the same periods in 2023.
• Gross profit decreased by 21.2% in Q3 2024 and 18% in 9M 2024 compared to the same periods in 2023.
• Operating income decreased by 15.8% in Q3 2024 and 16.9% in 9M 2024 compared to the same periods in 2023.
• Net income decreased by 9.4% in Q3 2024 and 11.1% in 9M 2024 compared to the same periods in 2023.
• Filshie Clip System sales were lower than projected.
• Litigation expenses for Filshie product claims increased significantly.
• The company expects a full-year 2024 revenue sales decline of 18% to 19% compared to 2023.

Risks

• The company faces risks related to fluctuations in foreign currency exchange rates.
• The company is involved in ongoing litigation related to Filshie product liability claims.
• The company's sales are dependent on a few key customers, including OEM customers.
• The company's future performance is subject to various market and economic conditions.
• The company's ability to achieve its financial objectives is subject to various risks and uncertainties.

Future Outlook

Management expects a full-year 2024 revenue sales decline of 18% to 19% compared to 2023, with a similar decline in net income. EPS will benefit from continued share repurchases. Sales in 4Q 2024 are expected to be lower than in 3Q 2024.

Management Comments

• Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to finance internal growth plans.
• The Company intends to utilize cash not needed to support normal operations in one or a combination of the following: 1) in general, to continue to invest at an opportune time in ways that will enhance future profitability; 2) to make additional investments in new technology and/or processes; and/or 3) to acquire a product line or company that will augment revenue and EPS growth and better utilize UTMDs existing infrastructure.
• If there are no better strategic uses for UTMDs cash, the Company will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued.

Industry Context

The medical device industry is competitive, and UTMD's results are affected by factors such as supply chain disruptions, customer demand, and regulatory changes. The decline in sales to a major OEM customer highlights the risk of customer concentration. The ongoing litigation related to the Filshie Clip System is also a significant factor impacting the company's performance.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, UTMD's gross profit margin of 58.0% in Q3 2024 and 59.3% in 9M 2024 is relatively high compared to some medical device companies, but lower than the previous year.
• The company's operating income margin of 33.4% in Q3 2024 and 33.6% in 9M 2024 is also relatively strong, but lower than the previous year.
• The company's adjusted consolidated EBITDA margin of 49.6% in Q3 2024 and 48.7% in 9M 2024 is also relatively strong, but lower than the previous year.
• The company's return on equity (ROE) of 8% (after dividends) and 12% (before dividends) for the nine-month period is lower than the company's target of 20%, indicating a need for improvement in profitability or asset utilization.
• Compared to companies like Medtronic (MDT) and Stryker (SYK), UTMD is a smaller company with a more focused product portfolio. Medtronic and Stryker have much larger revenue bases and more diversified product lines.
• UTMD's performance is also impacted by the specific market for its products, such as the Filshie Clip System, which is subject to product liability litigation.

Legal Proceedings

• UTMD is a party to Filshie clip U.S. product liability lawsuits still in discovery or pending summary judgment decisions.
• The Company does not expect the outcome of the Filshie clip litigation will be material to consolidated financial results.

Stakeholder Impact

• Shareholders are impacted by the decrease in earnings and share price, but also benefit from dividends and share repurchases.
• Employees may be impacted by cost-cutting measures and changes in the company's operations.
• Customers may be impacted by changes in product availability and pricing.
• Suppliers may be impacted by changes in the company's purchasing patterns.
• Creditors are impacted by the company's financial performance and ability to repay debts.

Next Steps

• Management will focus on bringing items 1) -4) of its 2024 plan to better fruition in 4Q 2024.
• The company will continue to monitor the impact of the decline in sales and take steps to mitigate the impact.
• The company will continue to evaluate strategic opportunities to enhance future profitability.

Key Dates

Keywords

medical devices, sales, earnings, Filshie Clip System, OEM, EBITDA, share repurchases, financial results, operating income, net income, litigation, stockholders equity